Holen Sie sich die Stockscreener-App
95.36
3.79%
-3.76
Handel nachbörslich:
95.53
0.17
+0.18%
Schlusskurs vom Vortag:
$99.12
Offen:
$98.19
24-Stunden-Volumen:
1.74M
Relative Volume:
0.56
Marktkapitalisierung:
$18.90B
Einnahmen:
$742.00K
Nettoeinkommen (Verlust:
$-1.13B
KGV:
-16.12
EPS:
-5.9165
Netto-Cashflow:
$-913.73M
1W Leistung:
+2.86%
1M Leistung:
-3.09%
6M Leistung:
+104.72%
1J Leistung:
+204.47%
1-Tages-Spanne:
$95.03
$98.73
1-Wochen-Bereich:
$94.04
$101.00
52-Wochen-Spanne:
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
650-481-6801
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
95.36 | 19.64B | 742.00K | -1.13B | -913.73M | -5.9165 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-02-27 | Fortgesetzt | UBS | Buy |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-12 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-09-05 | Eingeleitet | Truist | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Jefferies highlights Revolution Medicines, Inc. (RVMD)’s RAS(ON) platform in coverage initiation - MSN
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks
Revolution Medicines, Inc. (RVMD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revolution Medicines, Inc. (RVMD) stock price, news, quote and history - Yahoo Finance Singapore
Revolution Medicines begins phase 3 pancreatic cancer trial By Investing.com - Investing.com India
Revolution Medicines, Inc. (RVMDW) stock price, news, quote and history - Yahoo Finance Singapore
Revolution Medicines (RVMD) Begins Phase 3 Trial for Pancreatic Cancer Drug - GuruFocus
Wells Fargo Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $144 - Moomoo
Revolution Medicines begins phase 3 pancreatic cancer trial - investing.com
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer - The Manila Times
First patients enter global Phase 3 test in metastatic pancreatic cancer - Stock Titan
Tema Etfs LLC Decreases Position in Revolution Medicines, Inc. $RVMD - marketbeat.com
A Look At Revolution Medicines (RVMD) Valuation After Recent Share Price Momentum - Yahoo Finance
Piper Sandler Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $120 - Moomoo
Behavioral Patterns of RVMD and Institutional Flows - Stock Traders Daily
RVMD Stock Price, Quote & Chart | REVOLUTION MEDICINES INC (NASDAQ:RVMD) - ChartMill
Revolution Medicines' Readout of Trial for Pancreatic Cancer Drug Likely Positive, Oppenheimer Says - MarketScreener
Jefferies Highlights Revolution Medicines, Inc. (RVMD)’s RAS(ON) Platform in Coverage Initiation - Insider Monkey
Revolution Medicines (RVMD) price target increased by 10.02% to 136.84 - MSN
Is Revolution Medicines, Inc. (RVMD) A Good Stock To Buy Now? - Insider Monkey
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Rating of "Buy" by Analysts - MarketBeat
Revolution Medicines (RVMD) down 8.8% since last earnings report: Can it rebound? - MSN
Revolution Medicines (RVMD) Stock: Executive Sells $3.5M While Wall Street Upgrades to Strong-Buy - mexc.co
Revolution Medicines (RVMD) Stock Dips as Exec Sells $3.5M — But Analysts Aren’t Flinching - mexc.co
Vanguard (RVMD) files amendment showing 0 shares of Revolution Medicines - Stock Titan
Revolution Medicines (RVMD) Down 8.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Revolution Medicines (RVMD) Stock Dips as Exec Sells $3.5M — But Analysts Aren't Flinching - CoinCentral
Revolution Medicines exec Mancini sells $3.5m in shares - Investing.com
Revolution Medicines exec Mancini sells $3.5m in shares By Investing.com - Investing.com South Africa
Revolution Medicines (RVMD) officer exercises options, sells 37,450 shares under 10b5-1 plan - Stock Titan
Anthony Mancini of Revolution Medicines (RVMD) details stock options and RSUs - Stock Titan
Revolution Medicines (RVMD) CDO details initial option and RSU stake - Stock Titan
Revolution Medicines outlines $1.03B–$1.09B net loss guidance for 2025 amid expanded global RAS portfolio strategy - MSN
Revolution Medicines (NASDAQ:RVMD) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
[144] Revolution Medicines, Inc. SEC Filing - Stock Titan
MIL:1RVMD PB Ratio: 12.09 — 225% Above Median - GuruFocus
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst - Benzinga
Wedbush Reiterates Revolution Medicines (RVMD) Outperform Recommendation - MSN
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $427,962.96 in Stock - Defense World
Revolution Medicines (NASDAQ:RVMD) CFO Sells $273,868.44 in Stock - Defense World
(RVMD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Revolution Medicines, Inc.: Fundamental Analysis and Financial Ratings | 1RVMD | US76155X1000 - marketscreener.com
Piper Sandler Initiates Coverage of Revolution Medicines (RVMD) with an Overweight Rating - MSN
A Look At Revolution Medicines (RVMD) Valuation After AACR RAS(ON) Pipeline Data Catalyst - simplywall.st
Revolution Medicines COO Horn sells $455,918 in shares By Investing.com - Investing.com South Africa
Revolution Medicines Eyes Guidance with Mixed Signals from Financial Reports - timothysykes.com
Revolution Medicines rises on daraxonrasib data that supports phase 3 program - MSN
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):